SCHEMBL7464482

SCHEMBL7464482

CCCn1cnc2c1c(=O)[nH]c(=O)n2CC

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 6/20 0.86
PDE4B Q07343 6/20 0.86
PDE4C Q08493 6/20 0.86
PDE4D Q08499 6/20 0.86
ADORA2A P29274 5/20 0.86
MEN1 O00255 2/20 0.72
KMT2A Q03164 2/20 0.72
ALDH1A1 P00352 1/20 0.72
BRD4 O60885 4/20 0.71
BRD2 P25440 2/20 0.71
BRD3 Q15059 2/20 0.71
BRDT Q58F21 2/20 0.71
ADORA2B P29275 1/20 0.54
KDM4E B2RXH2 1/20 0.51
LMNA P02545 1/20 0.51
POLB P06746 1/20 0.51
MAPK1 P28482 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.49
PDE1A P54750 1/20 0.49
PDE1B Q01064 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3902928 0.93 PDE4A (1.00) PDE4APDE4BPDE4CPDE4DADORA2A
SCHEMBL7031729 0.92 MEN1 (0.87) PDE4APDE4BPDE4CPDE4DADORA2A
SCHEMBL516463 0.89 PDE4A (0.81) PDE4APDE4BPDE4CPDE4DADORA2A
SCHEMBL21381257 0.88 PDE4A (1.00) PDE4APDE4BPDE4CPDE4DADORA2A
SCHEMBL9565477 0.86 PDE4A (0.65) PDE4APDE4BPDE4CPDE4DADORA2A
SCHEMBL11462282 0.85 PDE4A (0.64) PDE4APDE4BPDE4CPDE4DADORA2A
SCHEMBL1495090 0.85 PDE4A (0.76) PDE4APDE4BPDE4CPDE4DADORA2A
SCHEMBL7457891 0.84 MEN1 (1.00) PDE4APDE4BPDE4CPDE4DADORA2A
SCHEMBL27600173 0.84 BRD4 (0.70) PDE4APDE4BPDE4CPDE4DADORA2A
SCHEMBL7763730 0.83 ADORA2A (0.82) PDE4APDE4BPDE4CPDE4DADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0960884-B1 Process for the production of 3,7-dialkylxanthins from 3-alkylxanthins AVENTIS PHARMA GMBH (DE) 2002-10-09 EP claimed
EP-0597377-B1 Process for the production of 3,7-Dialkylxanthine from 3-Alkylxanthine AVENTIS PHARMA GMBH (DE) 2000-08-16 EP claimed
EP-0960884-A1 Process for the production of 3,7-dialkylxanthins from 3-alkylxanthins HOECHST AKTIENGESELLSCHAFT (DE) 1999-12-01 EP claimed
US-5475107-A Process for obtaining 3,7-dialkylxanthines from 3-alkyl-xanthines HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1995-12-12 US claimed
EP-0597377-A1 Process for the production of 3,7-Dialkylxanthine from 3-Alkylxanthine HOECHST AKTIENGESELLSCHAFT (DE) 1994-05-18 EP claimed
EP-0960884-B1 Process for the production of 3,7-dialkylxanthins from 3-alkylxanthins AVENTIS PHARMA GMBH (DE) 2002-10-09 EP disclosed
EP-0771813-B1 Alkylxanthine phosphonates and alkylxanthine phosphine oxydes and their use as medicines HOECHST AG (DE) 2002-01-16 EP disclosed
EP-0597377-B1 Process for the production of 3,7-Dialkylxanthine from 3-Alkylxanthine AVENTIS PHARMA GMBH (DE) 2000-08-16 EP disclosed
EP-0960884-A1 Process for the production of 3,7-dialkylxanthins from 3-alkylxanthins HOECHST AKTIENGESELLSCHAFT (DE) 1999-12-01 EP disclosed
US-5922868-A 1-(4,4-ETHYLENEDIOXY-3-METHYLPENTYL)-3-METHYL-7-PROPYLXANTHINE HOECHST AKTIENGESELLSCHAFT (DE) 1999-07-13 US disclosed
US-5728686-A TREATMENT OF MUSCULAR DYSTROPHY HOECHST AKTIENGESELLSCHAFT (DE) 1998-03-17 US disclosed
EP-0771813-A1 Alkylxanthine phosphonates and alkylxanthine phosphine oxydes and their use as medicines HOECHST AKTIENGESELLSCHAFT (DE) 1997-05-07 EP disclosed
EP-0413278-B1 Use of xanthine derivatives against peptic ulcers HOECHST JAPAN (JP) 1996-11-06 EP disclosed
US-5475107-A Process for obtaining 3,7-dialkylxanthines from 3-alkyl-xanthines HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1995-12-12 US disclosed
EP-0597377-A1 Process for the production of 3,7-Dialkylxanthine from 3-Alkylxanthine HOECHST AKTIENGESELLSCHAFT (DE) 1994-05-18 EP disclosed
EP-0570831-A2 Use of Xanthinderivatives for treatment of cerebral nerve dammages after disruption of the blood circulation HOECHST AKTIENGESELLSCHAFT (DE) 1993-11-24 EP disclosed
US-5109003-A METHOD FOR THE TREATMENT OF PEPTIC ULCER DISEASE HOECHST JAPAN LIMITED (JP) 1992-04-28 US disclosed